SARS‐CoV‐2 and inflammatory responses: From mechanisms to the potential therapeutic use of intravenous immunoglobulin

A novel coronavirus (SARS-CoV-2) is responsible for a severe acute respiratory syndrome called disease 2019 (COVID-19). It originated in Wuhan, China, December 2019. Due to its extreme transmissibility with droplets and human contacts, few months, it has become pandemic. Nowadays, no effective therapy available, the scientific community moving find therapeutic choice fight this silent enemy. Studies are ongoing on several options, including antiviral agents, immunomodulant drugs, immunotherapy. viral features, ability start an inflammatory response that seems be fulcrum of COVID-19 pathogenic action, immunotherapy could represent promising alternative waiting vaccine. High-dose intravenous immunoglobulin (IVIg), already used other infectious diseases, help. The aim narrative review reassemble clinical experiences use IVIg rationale use.